Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment Results for Patients With CCCA
NCT04207931Phase 4Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 2018
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of doxycycline and triamcinolone acetonide in central centrifugal cicatricial alopecia (CCCA) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Central Scalp Alopecia Photographic Scale at 6 months. Started Apr 2018; status: recruiting.
02
Drugs
doxycyclinetriamcinolone acetonide
03
Conditions
central centrifugal cicatricial alopecia (CCCA)
Beyond the preview
Go deeper on NCT04207931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04207931.